Advocacy for Regulatory Flexibility in Rare Disease Therapies
Explore the urgent call for regulatory flexibility in rare disease therapies, as industry leaders seek solutions to expedite drug approvals amid strict FDA guidelines.
Explore the urgent call for regulatory flexibility in rare disease therapies, as industry leaders seek solutions to expedite drug approvals amid strict FDA guidelines.
The 2026 Medicare home health final rule release is delayed due to the government shutdown. Proposed 9% reimbursement cuts spark industry-wide concern and strategic responses from key providers and advocacy groups.